Cited by LncRNAs: Emerging biomarkers and therapeutic targets in rectal cancer

MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting DOI

Asif Ahmad Bhat, Obaid Afzal, Muhammad Afzal

et al.

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 253, P. 154991 - 154991

Published: Nov. 30, 2023

Language: Английский

Citations

Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in Lung inflammatory disease DOI

Manish Purohit, Gaurav Gupta, Obaid Afzal

et al.

Chemico-Biological Interactions, Journal Year: 2023, Volume and Issue: 371, P. 110334 - 110334

Published: Jan. 5, 2023

Language: Английский

Citations

From carcinogenesis to therapeutic avenues: lncRNAs and mTOR crosstalk in lung cancer DOI

Md Sadique Hussain, Abdulmalik Saleh Alfawaz Altamimi, Muhammad Afzal

et al.

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 253, P. 155015 - 155015

Published: Dec. 6, 2023

Language: Английский

Citations

Exosomal ncRNAs in liquid biopsies for lung cancer DOI

Md Sadique Hussain, Gaurav Gupta, Nehmat Ghaboura

et al.

Clinica Chimica Acta, Journal Year: 2024, Volume and Issue: 565, P. 119983 - 119983

Published: Oct. 3, 2024

Language: Английский

Citations

Circular RNAs in the KRAS pathway: Emerging players in cancer progression DOI

Md Sadique Hussain, Ehssan Moglad, Muhammad Afzal

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 256, P. 155259 - 155259

Published: March 11, 2024

Language: Английский

Citations

PVT1 lncRNA in lung cancer: A key player in tumorigenesis and therapeutic opportunities DOI

Mohammed Ageeli Hakami, Ali Hazazi, Farhan R. Khan

et al.

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 253, P. 155019 - 155019

Published: Dec. 7, 2023

Language: Английский

Citations

Safety and effectiveness of CIMAvax-EGF administered in community polyclinics DOI

Ramón A. Ortiz Carrodeguas,

Geidy Lorenzo Monteagudo,

Pedro P. Guerra Chaviano

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 13

Published: Jan. 18, 2024

In spite of the advances in immunotherapy and targeted therapies, lung cancer continues to be leading cause cancer-related death. The epidermal growth factor receptor is an established target for non-small cell (NSCLC), its overactivation by ligands can induce accelerated proliferation, angiogenesis, metastasis as well proinflammatory or immunosuppressive signals. CIMAvax-EGF (EGF)-depleting that approved treatment NSCLC patients Cuba. study was designed a phase IV trial characterize safety effectiveness advanced treated 119 community polyclinics 24 hospitals. consisted four bi-weekly doses followed monthly boosters. Overall, 741 ineligible further cancer-specific were enrolled. safe, most common adverse events mild-to-moderate injection site reactions, fever, chills, tremors, headache. For completing loading doses, median survival 9.9 months. individuals achieving at least stable disease frontline vaccination induction, 12 Most functional activities symptoms evaluated through European Organisation Research Treatment Cancer (EORTC) QLQ-C30 questionnaire improved over time. conclusion, this real-world demonstrated safe effective who vaccinated maintenance scenario. A larger effect seen subjects with poor prognosis like those squamous tumors high EGF levels. Remarkably, community-based intervention very important because it feasibility treating active primary care institutions. addition CIMAvax-EGF, received supportive clinic. Vaccine administration family doctors reduced patients’ burden on medical oncology services continued providing chemotherapy other complex therapies. We conclude constitute optimal scenario administering vaccines are require prolonged cancer, despite continuous deterioration their general condition. Clinical registration https://rpcec.sld.cu/trials/RPCEC00000205-En , identifier RPCEC00000205.

Language: Английский

Citations

Targeting notch-related lncRNAs in cancer: Insights into molecular regulation and therapeutic potential DOI

Raihan Siddique,

Gaurav Gupta,

Johar MGM

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 257, P. 155282 - 155282

Published: April 1, 2024

Language: Английский

Citations

Ferroptosis and circular RNAs: new horizons in cancer therapy. DOI

Asif Ahmad Bhat,

Neelima Kukreti,

Muhammad Afzal

et al.

PubMed, Journal Year: 2024, Volume and Issue: 23, P. 570 - 599

Published: Jan. 1, 2024

Cancer poses intricate challenges to treatment due its complexity and diversity. Ferroptosis circular RNAs (circRNAs) are emerging as innovative therapeutic avenues amid the evolving landscape of cancer therapy. Extensive investigations into circRNAs reveal their diverse roles, ranging from molecular regulators pivotal influencers ferroptosis in cell lines. The results underscore significance modulating pathways that impact crucial aspects development, including survival, proliferation, metastasis. A detailed analysis delineates these pathways, shedding light on mechanisms through which influence ferroptosis. Building upon recent experimental findings, study evaluates potential targeting induce By identifying specific associated with etiology cancer, this paves way for development targeted therapeutics exploit vulnerabilities cells. This review consolidates existing understanding circRNAs, emphasizing role therapy providing impetus ongoing research dynamic field. See also graphical abstract(Fig. 1).

Language: Английский

Citations

Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition DOI

Mohammed M. Amin,

Gamal El‐Din A. Abuo‐Rahma, Montaser Sh. A. Shaykoon

et al.

Bioorganic Chemistry, Journal Year: 2023, Volume and Issue: 134, P. 106444 - 106444

Published: Feb. 25, 2023

Language: Английский

Citations